Jim Cramer says Microsoft (MSFT) will report a decent quarter, thanks to Windows 10, but he wishes the company would make an acquisition. Cramer discussed Microsoft while answering viewers’ social media questions from the floor of the New York Stock Exchange on Tuesday. ‘I actually wish they would buy Salesforce (CRM) in order to be able to get to that cloud growth, which we know from IBM (IBM) is so key,' said Cramer. Cramer said at $43 or $44, Microsoft is a terrific price, and he added it can move up to $48 or $49 from current levels. Cramer was asked about Lending Tree (TREE) ahead of its earnings. Cramer said when it comes to financials, he’s a Wells Fargo (WFC) guy. Cramer was also asked about WhiteWave (WWAV), which was downgraded to sell by Goldman Sachs. Cramer said he believes the analyst is looking at WhiteWave as in the same category as Whole Foods (WFM) or The Fresh Market (TFM), which are not doing well. But Cramer said WhiteWave has a plant-based foods portfolio, which is what consumers want. He thinks the company will be bought if the stock goes any lower. Cramer answers viewers’ questions on social media each day. Find him on Facebook, and on Twitter, he’s @JimCramer. Send him a questions using #CramerQ. Jim Cramer manages the Action Alerts PLUS portfolio.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.